Prevalence of randomised controlled trials in Japanese cardiovascular journals: a descriptive study

Tasuku Matsuyama,1 Tomoko Fujii,2 Jiro Takeuchi,3 Masahiko Hara,4 Tetsuhisa Kitamura5

ABSTRACT

Background Little is known about the recent proportion and trends of randomised controlled trials (RCTs) published in Japanese cardiovascular journals. Methods and results This study retrospectively reviewed all original research articles published between 2006 and 2015 in six English-language journals issued by societies related to cardiovascular medicine in Japan. All these journals had been indexed in PubMed for more than 5 years until 2015. We examined the 2-year trends in the prevalence of RCTs, as well as the types of study subjects and interventions investigated. In addition, we applied a multivariable logistic regression analysis to assess the factors related to the publication of RCTs. A total of 7117 articles were eligible for our analyses. The proportion of RCTs among Japanese journals was 3.5% (252/7117). No significant change in the prevalence of RCTs among all included journals was noted (3.8% vs 3.1%, p=0.751). RCTs related to ischaemic heart disease were the most frequently published (85/252, 33.7%). In the multivariable analysis, a male first author (adjusted OR (AOR) 1.97; 95% CI 1.30 to 2.99) and reports from Asia (AOR 1.62; 95% CI 1.19 to 2.21) were significantly associated with the publication of RCTs. Conclusions In Japanese cardiovascular journals, RCTs accounted for 3.5% of all original research articles published, and there was no change in the prevalence of RCTs during the study period.

INTRODUCTION

More than 17 million people worldwide die from cardiovascular diseases every year, accounting for an estimated 31% of all deaths.1 In Japan, heart diseases were the second leading cause of death in 2012,2 while the cost of treating cardiovascular diseases accounted for approximately 20% of all national medical expenses, the highest percentage among all illnesses.3 The financial burden is expected to increase with population ageing in Japan, as in other industrialised countries.4,5 Thus, the effective prevention of cardiovascular diseases and interventions to treat them represent one of the most important issues in industrialised countries.1

Randomised controlled trials (RCTs) are considered to be one of the most valuable study designs for investigating the causal relationships between interventions and their possible effects.3 Evidence-based interventions may be able to reduce the burden of disability and death from heart diseases. Therefore, the results of RCTs make an essential contribution to the guidelines for any intervention.4 The number of RCTs published worldwide is showing a tendency to rise significantly,1 and the number of clinical trials in the field of cardiology, including RCTs, has been increasing.8 Hayashino and colleagues reported that the proportion of RCTs was 2.3% of all Japanese research articles published in the top 10 foreign cardiovascular journals in the 1990s; however, little is known about the recent proportion and trend of RCTs published in Japanese cardiovascular journals.

The aim of this study was to assess the prevalence of the RCTs published in Japanese cardiovascular journals that have been published in English for a period of years. In addition, we sought to determine the types of study patients and the interventions investigated in those studies.

METHODS

This was a retrospective descriptive study assessing the prevalence of RCTs among original research articles published in Japanese cardiovascular journals from 2006 to 2015. We examined their changes over time among journals, as well as the type of study subjects and interventions. As this study consisted only of a journal review and did not involve individual patients, ethical approval was not required.

Data collection

Inclusion and exclusion criteria

We selected all the six journals that were published in English by societies in Japan related to cardiovascular disease and that had been indexed in PubMed for more than 5 years until the year of 2015. We excluded journals published by societies that had both Japanese and overseas parts. The six journals were as follows: Circulation Journal, Journal of Cardiology (JC), Journal of Atherosclerosis and Thrombosis, Hypertension Research (HR), Heart and Vessels and International Heart Journal (IHJ).

The total number of authors, their first and last names, the country where the study was conducted and the article type, study subjects and study design were extracted from the full text of the articles. Data for original research articles, including meta-analyses, published in the six journals from January 2006 to December 2015 were analysed, but short papers, case reports, review articles, editorials and letters were excluded.

Variables of interest

For each original research article, the following data items were collected: year of publication, journal, gender of first author (male, female, group and unknown), country of first author’s affiliation (Japan, overseas Asian and non-Asian), type of first

To cite: Matsuyama T, Fujii T, Takeuchi J, et al. Heart Asia 2017;9:1–5. doi:10.1136/heartasia-2017-010929
author’s affiliation (university and non-university), total number of authors, corresponding author (first author and others) and study design (RCT, non-RCT human studies, animal studies and others). RCTs were defined as clinical studies whose study subjects were human and were randomly assigned among several groups and which investigated the efficacy of an intervention such as treatment. Only articles that reported the main results of RCTs were included in our analysis, whereas articles that only reported subgroup analysis and protocol articles were considered ineligible. The target disease of each RCT was classified into the following categories: ischaemic heart disease (IHD), hypertension, heart failure, dyslipidaemia, atrial fibrillation, cardiac surgery, chronic kidney disease, healthy volunteer, diabetes mellitus and others. In addition, the type of main intervention in each RCT was determined as drug, procedure, device or others. This study included the following Asian countries: China, Republic of Korea, Taiwan, India, Iran and Turkey.

The gender of the first author was noted, based on inspection of the first name. If the gender was not clearly indicated by the name, institutional websites, social media accounts that listed their publications (such as ResearchGate, Researchmap, LinkedIn and Facebook) and internet search engines (such as Google) were used to find photographs. Any first authors whose genders were not clearly identifiable were classified as ‘unknown’. The total number of authors was defined as the count of the named authors, excluding any group listed at the end.

Data quality
Four reviewers (TM, TF, JT and TK) used a standardised data collection sheet to collect data. Reviewers retrieved data independently, and the data were double-checked. Discrepancies were resolved through discussion among the reviewers.

Statistical analysis
We investigated the 2-year trend of study characteristics of all included articles using the Cochran-Armitage trend test for categorical variables and the Jonckheere-Terpstra test for continuous variables. The 2-year trends in the prevalence of RCTs by journal and by year of publication were also evaluated using the Cochran-Armitage trend test. We applied univariable and multivariable logistic regression analyses and calculated crude or adjusted ORs (AORs) and their 95% CIs to assess the factors related to the publication of RCTs. The factors included the following independent variables: author gender, location of first author’s affiliation, type of first author’s affiliation, total number of authors, corresponding author and publication year. All statistical analyses were performed using SPSS statistical package V22.0J. All tests were two tailed; p values of <0.05 were considered statistically significant.

RESULTS
Among the six journals, JC had been published for the last 8 years, whereas the other five journals had a history of publication that spanned the entire 10 years of the study period. During the study period, we retrieved 7124 original articles; after seven retracted articles had been excluded, 7117 articles were eligible for our final analyses.

The study characteristics of the included original articles by the year of publication are shown in table 1. There was no significant change in the prevalence of a female first author or in the first author’s affiliation (p for trend 0.066 and p for trend 0.298, respectively). The number of original articles from both Asian and non-Asian countries increased greatly (from 19.1% to 23.4%, p for trend 0.001 and from 8.0% to 15.2%, p<0.001, respectively). The proportion of RCTs among Japanese journals was 3.5% (252/7117). No significant change in the prevalence of RCTs among all included journals was noted (3.8% vs 3.1%, p for trend 0.751).

Table 2 shows the prevalence of RCTs by journal and by year of publication. HR showed a slight increase from 1.1% (4/376) to 3.4% (8/234) (p=0.017), whereas there was a trivial decrease for IHJ (4.1% (5/121) to 2.5% (4/157), p=0.045). There was no significant change in the prevalence of RCTs in the other four journals. The types of patients and interventions in the 252 eligible RCTs are shown in table 3. The largest proportion of patients was 33.7% (85/252) with IHD, followed by 13.5% (34/252) with hypertension and 12.7% (32/252) with heart failure. As for the type of intervention, research into drug effects was the most frequent (78.2%, 197/252).

We assessed the factors associated with the publication of RCTs. Male first author (AOR 1.97; 95% CI 1.30 to 2.99) and first author being corresponding author (AOR 1.60; 95% CI 1.22 to 2.10) were positively associated with RCTs. The RCTs from Asian countries were more likely to be published compared with ones from Japan (AOR 1.62; 95% CI 1.19 to 2.21), whereas those from non-Asian countries showed no significant difference (AOR 0.72; 95% CI 0.47 to 1.11) (table 4).

DISCUSSION
Our findings demonstrated that the overall proportion of RCTs among all original research articles was 3.5% and that this showed no change during the study period. In addition, RCTs related to IHD were the most frequently published according to our data. In the multivariable analysis, a male first author and reports from Asia were significantly associated with the publication of RCTs. Our findings will provide fundamental information helpful for future directions in the cardiovascular field in Japan.

In this study, RCTs comprised 3.5% of all original research articles. In earlier reports, Hayashino and colleagues demonstrated that RCTs accounted for 2.1% of all research articles from Japan published in the top 10 cardiovascular journals overseas.6 Kuroki and colleagues reported that the proportion of RCTs among published articles in the gynaecology field was 35% in high impact factor journals, such as the New England Journal of Medicine, the Lancet, and the Journal of the American Medical Association, and 12% in journals with a moderate impact factor, similar to that of Japanese cardiovascular journals.10 This study only assessed the recent 10-year trends in the proportion of RCTs published in Japanese cardiovascular journals, and further continuous observation is needed to evaluate whether the proportion of RCTs in the cardiovascular field will increase or not.

We observed that RCTs related to IHD were the most frequently reported in Japanese cardiovascular journals during the study period. Kapoor and colleagues also demonstrated that clinical trials involving IHD made up the biggest group among all clinical trials on cardiovascular disease published from 1993 to 2013.3 The global burden of IHD is exceedingly large; IHD is the leading cause of death in the world, but even non-fatal disease affects patients’ lives negatively with the disabling symptoms of angina pectoris or ischaemic heart failure.11 However, age-standardised IHD incidence and mortality rates have actually decreased in most world regions, especially those with high incomes, over the last several decades.2 13 In Japan, age-standardised IHD incidence and mortality per 100 000 persons decreased from 111.0 and 79.5 in 1996 to 59.0 and 45.5 in 2013.8
2014, respectively. This is probably because active research into IHD may successfully improve lifestyle interventions (eg, weight management, smoking cessation or encouragement of physical activity), drug therapies for hypertension, dyslipidaemia or diabetes mellitus, and invasive procedures such as coronary interventions. However, despite the decline in age-standardised IHD incidence and mortality, population ageing continues to lead to a higher burden of IHD globally. Therefore, clinical trials involving other diseases whose incidence increases with population ageing, such as atrial fibrillation or heart failure, will also become more important.

In this study, the prevalence of randomised controlled trials by journal and year of publication

| Journal                                | Total (n=7117) | 2006–2007 (n=1121) | 2008–2009 (n=1415) | 2010–2011 (n=1544) | 2012–2013 (n=1507) | 2014–2015 (n=1530) | p for trend* |
|----------------------------------------|----------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------|
| Circulation Journal                    | 3.8 (43/1121)  | 2.4 (34/1415)     | 4.1 (63/1544)     | 4.3 (65/1507)     | 3.1 (47/1530)     | 0.751             |
| Heart and Vessels                      | 7.9 (8/101)    | 3.5 (4/115)       | 6.4 (10/156)      | 3.6 (6/165)       | 3.8 (7/185)       | 0.182             |
| Hypertension Research                  | 0.4 (1/252)    | 1.1 (4/376)       | 2.5 (8/321)       | 1.1 (3/263)       | 3.4 (8/234)       | 0.017             |
| International Heart Journal            | 7.5 (10/133)   | 4.1 (5/121)       | 4.5 (6/132)       | 3.2 (4/126)       | 2.5 (4/157)       | 0.045             |
| Journal of Atherosclerosis and Thrombosis | 2.9 (2/69)    | 0.8 (1/126)       | 4.3 (10/235)      | 3.3 (6/183)       | 4.4 (9/203)       | 0.226             |
| Journal of Cardiology                  | 1.5 (2/131)    | 5.9 (9/153)       | 5.6 (13/231)      | 1.9 (5/270)       | 0.644             |

Values are expressed as percentages (numbers) unless indicated otherwise.

*Comparisons between the five groups were evaluated with the Cochran-Armitage trend test.

IQR, first to third quartile.

Values are expressed as numbers (percentages) unless indicated otherwise.

*Comparisons between the five groups were evaluated with the Cochran-Armitage trend test for categorical variables and the Jonckheere-Terpstra test for continuous variables.

†Compared between female first author and others

‡Compared between RCT and all other studies.

RCT, randomised controlled trial.
internationally recognised since the 2000s. Importantly, globalisation can help foster cross-cultural understanding, widespread collaboration and the valuable exchange of ideas and products.18 The Japanese Circulation Society promotes the development of cardiovascular medicine in Japan and throughout all Asia and has created the Circulation Journal Asian Award for Asian cardiovascular researchers.19 The promotion might successfully attract a great number of Asian cardiovascular researchers. The present study underscored that females accounted for 18.7% of first authors of original research articles, whereas males were about twice as likely to be the first author of an RCT. Filardo and colleagues observed that the proportion of female first authors in original research articles was 34.0% among worldwide high-impact general medical journals.20 Gender inequality has been noted in Japan. For example, according to the Global Gender Gap Report 2016, Japan was ranked 111th out of 144 countries in terms of gender equality based on economic, political and health criteria.21 In Japan, the proportion of female physicians gradually increased from 16.5% in 2004 to 20.4% in 2014.22 As for the Japanese Circulation Society, female members accounted for 12.5% of all members in 2015, and there was only 1.4% increase compared with 11.1% in 2005. However, Yamauchi-Takahara demonstrated that the proportion of the female presenter at its annual scientific meeting increased from 11.0% in 2006 to 15.4% in 2015.23 Although there is no proven association between presenter at a scientific meeting and an increase in the number of any kinds of research articles, gender disparities have gradually improved,21 22 and further observation and efforts will be required to achieve gender equality.

**STUDY LIMITATIONS**

This study has several inherent limitations. First, some misclassification might have occurred because each reviewer retrieved data manually by reading the manuscript. However, to minimise errors, the data were double-checked. Second, our findings cannot be generalised to the whole of Japanese cardiovascular research, because we investigated only the six Japanese cardiovascular journals that have years of history of publication in English. RCTs might be submitted to other journals with a higher impact factor worldwide, and we were not able to determine how many times papers including RCTs published in Japanese cardiovascular journals were submitted to other journals. Third, we assessed the factors associated with RCTs, but we could not exclude possible residual confounding factors.

**Table 3** Type of patients and interventions in randomised controlled trials

|                      | Total (n=252) | Drug (n=197) | Procedure (n=40) | Device (n=10) | Others (n=5) |
|----------------------|--------------|-------------|-----------------|--------------|-------------|
| Ischaemic heart disease | 85 (33.7)    | 70 (35.5)   | 8 (20.0)        | 7 (70.0)     | 0 (0.0)     |
| Hypertension         | 34 (13.5)    | 30 (15.2)   | 3 (7.5)         | 0 (0.0)      | 1 (20.0)    |
| Heart failure        | 32 (12.7)    | 23 (11.7)   | 8 (20.0)        | 0 (0.0)      | 1 (20.0)    |
| Dyslipidaemia        | 25 (9.9)     | 24 (12.2)   | 0 (0.0)         | 0 (0.0)      | 1 (20.0)    |
| Atrial fibrillation  | 16 (6.3)     | 11 (5.6)    | 5 (12.5)        | 0 (0.0)      | 0 (0.0)     |
| Cardiac surgery      | 10 (4.0)     | 4 (2.0)     | 6 (15.0)        | 0 (0.0)      | 0 (0.0)     |
| Chronic kidney disease | 9 (3.6)     | 7 (3.6)     | 1 (2.5)         | 0 (0.0)      | 1 (20.0)    |
| Healthy volunteer    | 8 (3.2)      | 6 (3.0)     | 1 (2.5)         | 1 (10.0)     | 0 (0.0)     |
| Diabetes mellitus    | 2 (0.8)      | 2 (1.0)     | 0 (0.0)         | 0 (0.0)      | 0 (0.0)     |
| Others               | 31 (12.3)    | 20 (10.2)   | 8 (20.0)        | 2 (20.0)     | 1 (20.0)    |

Values are expressed as numbers (percentages).

**Table 4** Factors associated with randomised controlled trials

|                        | Total RCT (%) | Crude OR (95% CI) | p Value | Adjusted OR (95% CI) | p Value |
|------------------------|---------------|-------------------|---------|----------------------|---------|
| Gender of first author |               |                   |         |                      |         |
| Male                   | 5675 (226)    | 2.07 (1.36 to 3.04) | <0.001  | 1.97 (1.30 to 2.99) | 0.001   |
| Female                 | 1330 (26)     | Reference         |         | Reference            |         |
| Location of affiliation|               |                   |         |                      |         |
| Japan                  | 4632 (163)    | Reference         |         | Reference            |         |
| Asia                   | 1371 (64)     | 1.34 (1.00 to 1.80) | 0.051  | 1.62 (1.19 to 2.11) | 0.002   |
| Non-Asia               | 1002 (25)     | 0.70 (0.46 to 1.08) | 0.103  | 0.72 (0.47 to 1.11) | 0.133   |
| Affiliation            |               |                   |         |                      |         |
| University             | 5662 (207)    | 1.09 (0.80 to 1.50) | 0.589  | 1.21 (0.87 to 1.69) | 0.255   |
| Others                 | 1343 (45)     | Reference         |         | Reference            |         |
| Correspondence         |               |                   |         |                      |         |
| First author           | 3142 (136)    | 1.44 (1.13 to 1.84) | 0.003  | 1.60 (1.22 to 2.10) | 0.001   |
| Other                  | 3863 (116)    | Reference         |         | Reference            |         |
| Total no. of listed authors for increment of authors by one | 1.00 (0.97 to 1.04) | 0.859 | 1.01 (0.87 to 1.69) | 0.630 |
| Publication year (for increment of year by one) | 1.01 (0.96 to 1.05) | 0.766 | 1.02 (0.97 to 1.06) | 0.534 |

Analysed by eliminating 11 papers by a group author and 101 where the first author’s gender was unknown. RCT, randomised controlled trial.
CONCLUSION
Since the 2000s, RCTs accounted for 3.5% of all original research articles published in Japanese cardiovascular journals, and there was no change in the prevalence of RCTs over the last decade. Future continuous observation will be required to evaluate trends in the proportion of RCTs in Japanese cardiovascular journals.

Key messages

What is already known about this subject?
► The number of randomised controlled trials (RCTs) published worldwide is showing a tendency to rise significantly, and the number of clinical trials in the field of cardiology, including RCTs, has been increasing.

What might this study add?
► In Japanese cardiovascular journals, RCTs accounted for 3.5% of all original research articles published, and there was no change in the prevalence of RCTs during the study period from 2006 through 2015.

How might this impact on clinical practice?
► Our findings will provide fundamental information helpful for future directions in the cardiovascular field in Japan.

Acknowledgements We would like to thank Ms Ling Zha, Ms Rong Liu and Ms Son Hyesoon for determining the genders of authors in China, Taiwan and South Korea.

Contributors Conceived and designed the study: TM, TF, JT and TK. Analysed the data: TM, JT, MH and TK. Wrote the paper: TM, TF, MH and TK.

Competing interests None declared.

Patient consent As this study consisted only of a journal review and did not involve individual patients, ethical approval or any consents are not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement TM and TK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. World Health Organization. Programmes and projects: cardiovascular diseases. http://www.who.int/cardiovascular_diseases/en/ (accessed 10 Jan 2017).
2. Ministry of Health, Labour and Welfare. Vital statistics. http://www.mhlw.go.jp/toukei_hakusho/toukei/ (accessed 10 Jan 2017).
3. Ministry of Health, Labour and Welfare. Estimates of National Medical Care Expenditure. http://www.mhlw.go.jp/toukei/list/37-21.html (accessed 10 Jan 2017).
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933–44.
5. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:198–201.
6. The GRADE working group. The Grading of Recommendations Assessment, Development and Evaluation. http://www.gradeworkinggroup.org/ (accessed 10 Jan 2017).
7. Clinical Trials.gov. Trends, Charts, and Maps. https://clinicaltrials.gov/ct2/resources/trends#typesOfRegisteredStudies (accessed 10 Jan 2017).
8. Kapoor R, Sadvacha S, Zacks JS. An analysis of Global Research Trends in Cardiology over the last two decades. J Clin Diagn Res 2015;9:OC06–OC09.
9. Hayashino Y, Rahman M, Fukui T. Japan’s contribution to research on cardiovascular disease. Circ J 2003;67:103–6.
10. Kuroki YM, Alloworth JE, Pegeart JF. Methodology and analytic techniques used in clinical research: associations with journal impact factor. Obstet Gynecol 2009;114:877–84.
11. World Health Organization. The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed 10 Jan 2017).
12. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014;129:1493–501.
13. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 2014;129:1483–92.
14. Ministry of Health, Labour and Welfare. Patient survey. http://www.mhlw.go.jp/toukei/sakihin/koujihou/gaiyou.html (accessed 10 Jan 2017).
15. The japanese circulation Society. Guidelines for the primary prevention of ischemic heart disease revised version (JCS). 2012 http://www.j-circ.or.jp/guideline/pdf/CS2012_shimamoto_h.pdf (accessed 10 Jan 2017).
16. The japanese circulation Society. Guidelines for Secondary Prevention of Myocardial Infarction (JCS). 2011 http://www.j-circ.or.jp/guideline/pdf/CS2012_shimamoto_h.pdf (accessed 10 Jan 2017).
17. Judith K, Rose L. The rise of Asia: A Research Profile. https://www.elsevier.com/editors-update/story/publishing-trends/the-rise-of-asia-a-research-profile (accessed 1 Jul 2017).
18. Glickman SW, MChutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360:816–23.
19. The japanese circulation Society. Circulation Journal Asian Award. http://www2. convention.co.jp/jcs2017/contents/award/award05_02.html (accessed 10 Jan 2017).
20. Filardo G, da Graca B, Sassi DM, et al. Trends and comparison of female first authorship in high impact medical journals: observational study (1994-2014). BMJ 2016;352:i1847.
21. World Economic Forum. The global gender gap Report 2016. http://reports.weforum.org/global-gender-gap-report-2016/the-global-gender-gap-report-2016/ (accessed 10 Jan 2017).
22. Ministry of Health, Labour and Welfare. Survey of Physicians, Dentists and Pharmacists. http://www.mhlw.go.jp/toukei/list/33-20c.html (accessed 1 Jul 2017).
23. Yamashita-Takahara K. Policy of the japanese society of Ultrasonics in Medicine for the Women’s Carrier Support. Jap J Med Ultrasonics 2016;43.